It doesn’t mean we’re neglecting pediatric. Absolutely not. But we continue to push in adults, especially in female adults. We’ve signed up some really great influencers and have partnership with, like, Busy Phillips, which we announced very recently. You know, she’s talking about ADHD and her experience in ADHD and her experience with Qelbree as a product that has helped her tremendously. So we hope to continue the market education and encourage patients to step forward and talk about their disease, about their conditions, about the things that they struggle with every single day, and let them know that there are options out there. And these options don’t have to be stimulants. They don’t have to be controlled substances. And they can be a very good, well-tolerated non-stimulant that can be very effective, which is the case with Qelbree.
And every metric we’ve looked at Qelbree, and time goes on, we have more and more data and more evidence that the product really works. And it really works fast and it works well with kids and with adults. So, we will continue to invest in these areas and clearly as we get closer to the back to school season, we’ll make more investments and more prioritization of resources around the back-to-school season. Regarding 817 and the profile, again, I mean, we will reveal, of course, the data on May 20 — 23 of May. I mean, clearly we want a product that works. I mean, at the end of the day when you look at epilepsy and the landscape there are so many agents out there and we’ve been in that space for so many years before with Oxtellar XR, Trokendi XR or even Carbatrol way back and many patients alive, I referred to earlier, they become refractory unfortunately.
And they don’t respond to as many vacations. And these patients end up on weighing more than one or two drugs eventually. And therefore, you need a drug that really works and works well. And hopefully works well, so that you avoid having the patients who progressed and even become refractory. And clearly that’s been of the gold standard that you’re looking for. There’s still tried to treat patients early. And you make them to be responsive to these medications that are responsive. And the progress for the worsening of their condition is delayed as time goes on. So 817 from what we’ve seen so far, looks like as an effective medication. You know from the data we’ve shared earlier back in October, our R&D Day as well as some of the patients we have in Australia are weighing that in the early, early stage.
So we hope to have a profile of a drug that actually works well. And again in Qelbree given its mode of action and so forth, if it does also have some pro cognitive attributes that would be huge. That would be huge specifically in this patient population. So we will see as the analysis. We’re literally completing a lot of that analysis as we speak even though we had a little bit more patients than we initially expected and we’ve shared all that on May 23rd.
Stacy Ku: Okay. Understood. Thank you so much.
Operator: Thank you. [Operator Instructions] And our next question comes from Annabel with Stifel. Go ahead, Annabel.
Jack Padovano: Hi. This is Jack on for Annabel. Thanks for taking our question. And so I know you’ve mentioned previously that about 30% of Qelbree patients are treatment-naive and the other 70% are switches from existing therapies. Are there any differences in the responses that these two patient populations have to calibrate when it comes to things like speed of effect onset essentially trying to ask here is there a better onboarding strategy or new both populations from identically once they initiate Qelbree?
Jack Khattar: Not really. I mean it’s a pretty remarkable. The consistency of the feedback we get from the field on whether you have the patient first of all is pediatric or is it all or where the patient has come from to the Qelbree franchise. As far as the efficacy of Qelbree, it works fast as I mentioned earlier. I mean between, a week to two weeks depending on whether you need to titrate that you have an older patient get unlike an adolescent? Or do you have an adult obviously you have to titrate and whether the physician despite rating has on the label on it by titrating a little bit slower just because they choose to do that right? But nevertheless patients feel and they start seeing the improvements during the titration.
And during January and February the onset of action is fairly quick actually and some of the survey results that we have seen overtime since we launched this product. The physicians will use Qelbree and have used that data for many years. They tell you Qelbree works within a week to two weeks and on an average Strattera is at least four or five weeks. I mean even in Europe, they’ve known it themselves and they see them given the experience they’ve had with Strattera. So we know that the product is working really well, regardless of whether you’re a switch or you are completely naive new patients will bet on Qelbree from the beginning.
Jack Padovano: Got it. And then just kind of ask one more on speaking about physician feedback. So I know that you’re looking at Qelbree in the co-morbid mood symptoms, more formally in the Phase 4 and we’re going to see that data eventually. But in the meantime, have you heard any anecdotal real-world reports from physicians maybe not involved in the trial and about how Qelbree might be performing in these kind of patients population..
Jack Khattar: We actually — first started hearing about it and put simply — even way back when we were doing the studies from some investigators who at that time again, anecdotally this was nothing like portable data collection or anything anecdotally, telling us you know, we see – and that aligns us even on top of it. So we don’t know whether the patient they’re talking about is taking Qelbree or taking placebo at that time. But they were telling us, it looks like the patient is not just getting better because they can pay more attention or focus or whatever, they’re just feeling better overall in general. So, it’s more about the whole mood of the patient’s overall well-being of the patient, not just focus attention for every — impulsivity or hyperactivity or anything specific to ADHD and we would have these investigators on that’s — do you have an idea then again not knowing what that patient whoever they are referring to.
